Hereditary factors play a key role in the risk of developing several cancers.
1,2 Identification of a germline predisposition can have important implications for treatment decisions, risk-reducing interventions, cancer screening, and germline testing for affected patients and their close relatives. Prior studies
3-5 have estimated the prevalence of germline cancer susceptibility in patients with breast, prostate, and colorectal cancer. However, most of these estimates have been from registry populations, genetic testing companies, and high-risk cancer clinics, likely producing a referral and ascertainment bias. Selection for genetic testing has traditionally been based on pathologic features of the cancer, age at diagnosis, family history of cancer, and other factors stipulated in clinical practice guidelines.
6 Few studies
7,8 have compared the prevalence of germline findings in patients with cancer unselected by practice guidelines. It remains unclear what the impact of broad-based testing for inherited germline variants is in patients with cancer compared with more traditional approaches of selection for genetic testing.